Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed
Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the […]
MFN News Items
Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer
Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks
Isofol to present at the 10th Annual Biotech Showcase Conference
Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief Commercial Officer Sven
Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018
Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation
Isofol appoints Gustaf Albèrt as Chief Financial Officer
Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience from leading financial positions, Albèrt
Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities
Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in
Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer
Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal
From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer
Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study
Isofols appoints Sven Erickson as Chief Commercial Officer
In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of Sven Erickson as Chief
Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®
Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera,